If a family member has been diagnosed with colorectal, gastric, or pancreatic cancer, hereditary risk testing may be one of the most important steps you can take. Here is a complete, evidence-based guide to recommended genes, syndromes, and direct-to-consumer options available today.
Hereditary factors account for approximately 5–10% of all cancers. In gastrointestinal malignancies, several well-characterized syndromes — caused by inherited mutations in specific genes — dramatically increase an individual's lifetime risk of colorectal, gastric, and pancreatic cancers. Identifying these mutations enables early surveillance, risk-reducing interventions, and potentially life-saving decisions for the entire family.
The initial and most essential step before any test is a thorough family history. Age at diagnosis, cancer type, and whether relatives are on the maternal or paternal side are all critical data points that guide which test — or which panel — is most appropriate.
Several inherited syndromes are directly linked to elevated digestive cancer risk. Understanding which syndrome may be present in a family helps clinicians and genetic counselors select the most targeted test.
Lynch syndrome is the most common hereditary GI cancer syndrome. It is caused by germline mutations in DNA mismatch repair (MMR) genes and confers a significantly elevated lifetime risk of colorectal, endometrial, gastric, small intestinal, and urological cancers, often presenting at younger ages than sporadic cases.
Genes tested: MLH1, MSH2, MSH6, PMS2, EPCAM
FAP is characterized by hundreds to thousands of colorectal polyps beginning in adolescence, with near-certain progression to colorectal cancer if untreated. MAP is an autosomal recessive variant with a similar but milder phenotype.
Genes tested: APC (FAP), MUTYH (MAP)
HDGC is driven primarily by mutations in the CDH1 gene encoding E-cadherin. Approximately 15–20% of gastric cancer patients carry pathogenic variants in hereditary cancer genes. Lobular breast cancer risk is also elevated in CDH1 carriers.
Genes tested: CDH1, CTNNA1
Between 11% and 20% of pancreatic cancer patients carry an identifiable pathogenic germline variant. No single dominant syndrome explains hereditary pancreatic cancer; rather, mutations in several genes confer moderate to high risk.
Genes tested: BRCA1, BRCA2, PALB2, ATM, CDKN2A, STK11
These hamartomatous polyposis conditions involve distinctive polyp types and carry elevated risk of GI cancers. Genetic findings are present in 40–72% of affected individuals depending on polyp burden.
Genes tested: STK11 (Peutz–Jeghers), SMAD4, BMPR1A (Juvenile Polyposis)
Core Lynch syndrome mismatch repair genes. Elevated risk for colorectal, endometrial, and gastric cancers.
Lynch syndrome variants with slightly lower penetrance. Colorectal and endometrial risk predominate.
Classic FAP. Near-100% lifetime colorectal cancer risk without prophylactic colectomy.
Base excision repair gene. Biallelic mutations cause MAP with elevated colorectal cancer risk.
Hereditary diffuse gastric cancer. Also raises lobular breast cancer risk.
Well-known for breast/ovarian risk, but also significantly elevate pancreatic cancer risk.
Moderate-to-high risk genes for pancreatic and breast cancer. Increasingly recognized in GI panels.
Peutz–Jeghers syndrome. Hamartomatous polyps throughout the GI tract; elevated cancer risk.
Current clinical guidelines recommend genetic counseling and testing in individuals who have:
Ideally, testing begins with the family member who had cancer, as they are the most informative starting point for identifying the causative variant.
Access to genetic testing has expanded significantly. Two broad models exist for individuals who wish to pursue testing outside the traditional clinical referral pathway.
These tests can be ordered online and return results through a digital portal without physician involvement or genetic counseling. The primary company in this space with FDA authorization for cancer risk is 23andMe, whose test covers 44 BRCA1/BRCA2 variants and two MUTYH variants. However, it is critical to understand that this covers only a small fraction of all known pathogenic variants — approximately 80% of cancer-causing BRCA mutations are not detected by this approach. A negative result is therefore not reassuring in a meaningful clinical sense.
This is the more clinically relevant model. The consumer initiates the process online, but a physician — either their own or one affiliated with the testing company — formally orders the test. Results are typically returned with genetic counseling options. This approach uses the same clinical-grade multigene panel technology available in hospital settings.
| Company | Model | GI Cancer Genes | Counseling | Clinical Grade |
|---|---|---|---|---|
| 23andMe | True DTC | 44 BRCA variants, 2 MUTYH variants | None included | Limited |
| Invitae | Consumer-initiated / Physician-ordered | Comprehensive multi-gene panels incl. Lynch, FAP, HDGC, pancreatic | Available | Yes (CLIA/CAP) |
| Color Genomics | Consumer-initiated / Physician-ordered | 30+ hereditary cancer genes including GI-relevant panel | Included | Yes (CLIA/CAP) |
| Myriad Genetics | Consumer-initiated / Physician-ordered | myRisk panel: 48 genes including Lynch, FAP, gastric, pancreatic | Available | Yes (CLIA/CAP) |
| Exact Sciences (Riskguard) | Physician-ordered (can be consumer-initiated) | Comprehensive hereditary cancer panel; GI-focused options available | Available | Yes (CLIA/CAP) |
| Guardant Hereditary | Physician-ordered | 82-gene germline panel covering 12+ tumor types incl. colorectal, gastric, pancreatic | Recommended | Yes |
Modern next-generation sequencing technology allows laboratories to analyze dozens of genes simultaneously at reduced cost and turnaround time. Multigene panel tests (MGPTs) are now the standard approach when multiple hereditary syndromes could explain a family's cancer pattern — which is common in families with overlapping GI and non-GI malignancies.
The National Comprehensive Cancer Network (NCCN) endorses MGPT when a personal or family history meets criteria for more than one syndrome, when established guidelines are not fully met but suspicion persists, or when family history is limited or unknown. The key is ensuring the laboratory is accredited (CAP-certified and CLIA-compliant) and that results are interpreted with genetic counseling support.
Most major insurance plans, including Medicare, cover genetic testing when medically indicated based on personal or family history criteria. For those without coverage or who do not meet insurance thresholds, several clinical-grade laboratories offer self-pay options at substantially reduced rates, as well as financial assistance programs. Consumer-initiated platforms have also made entry-level screening more affordable, though at the cost of comprehensiveness.
A note of caution: some less reputable labs sell genetic tests at health fairs or online with minimal clinical oversight. Always verify that any laboratory used holds current CAP accreditation and CLIA certification.
Testing for Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM) and APC/MUTYH for polyposis syndromes is recommended, particularly if a first-degree relative was diagnosed before age 50 or if multiple relatives have been affected.
Yes, to a limited extent. 23andMe offers an FDA-authorized DTC test covering select BRCA and MUTYH variants. However, for comprehensive and clinically actionable results, consumer-initiated platforms such as Invitae or Color that work through a physician are a better option. Many now facilitate physician ordering on the consumer's behalf.
Key genes include BRCA1, BRCA2, PALB2, ATM, CDKN2A, and STK11. A multigene panel is the preferred approach as it assesses all relevant genes simultaneously and captures overlapping risk syndromes.
DTC tests provide limited cancer risk information. For example, 23andMe's BRCA test misses approximately 80% of pathogenic variants. Clinical-grade panel tests from CLIA/CAP-accredited laboratories are substantially more comprehensive and appropriate for medical decision-making.
When possible, testing should begin with the family member who had cancer. They are the most informative candidate — identifying the specific mutation in them enables precise "cascade testing" in unaffected relatives, which is more accurate than testing relatives first.